Sympathoinhibitory effect of sacubitril-valsartan in heart failure with reduced ejection fraction: A pilot study

• Published in: Autonomic neuroscience 2021-11, Vol.235, p.102834-102834, Article 102834
• Main Authors: Bunsawat, Kanokwan, Ratchford, Stephen M., Alpenglow, Jeremy K., Stehlik, Josef, Smith, Adam S., Richardson, Russell S., Wray, D. Walter
• Format: Article
• Language: English
• Subjects: Aminobutyrates - therapeutic use; Angiotensin Receptor Antagonists - therapeutic use; Biphenyl Compounds; Drug Combinations; Entresto; Heart failure; Heart Failure - drug therapy; Humans; Muscle sympathetic nerve activity; Pilot Projects; Prospective Studies; Stroke Volume; Sympathetic nervous system; Treatment Outcome; Valsartan
• ISSN: 1566-0702; 1872-7484
• DOI: 10.1016/j.autneu.2021.102834

Chronic sympathetic nervous system (SNS) overactivity, characteristic of heart failure (HF) with reduced ejection fraction (HFrEF), is associated with poor prognosis and contributes to increased mortality risk. Sacubitril-valsartan is a recently approved, first-in-class, angiotensin receptor neprilysin inhibitor (ARNI) drug that markedly reduces the risks of death from cardiovascular causes and hospitalization for HF in patients with HFrEF, but the physiological mechanisms underlying these benefits are not fully understood. This single-arm, open-label, prospective study sought to test the hypothesis that short-term treatment with sacubitril-valsartan reduces SNS activity, measured directly via muscle sympathetic nerve activity (MSNA), in patients with HFrEF. MSNA, heart rate (HR), and arterial blood pressure (BP) were assessed in stable Class II and III patients with HFrEF (n = 9, 69 ± 8 yrs.; 28.6 ± 3.6 kg/m2) on contemporary, guideline-directed medical treatment who were subsequently started on sacubitril-valsartan. These measurements were repeated after two months of treatment with sacubitril-valsartan. Sacubitril-valsartan reduced MSNA burst frequency (baseline: 43 ± 10 bursts/min; 2-month: 36 ± 10 bursts/min, p = 0.05) and burst incidence (baseline: 68 ± 16 bursts/100 heartbeats; 2-month: 55 ± 16 bursts/100 heartbeats, p = 0.02), while HR and BP were unchanged following the treatment (p > 0.05). These preliminary findings provide new evidence regarding the ability of sacubitril-valsartan to rapidly reduce SNS activity in patients with HFrEF, suggesting the presence of a novel sympathoinhibitory effect of this new drug class.